Drug Profile
PH 50
Alternative Names: N-1177; PH-50Latest Information Update: 08 Jul 2011
Price :
$50
*
At a glance
- Originator Elan Corporation; IMCOR Pharmaceutical
- Class Iodinated contrast media
- Mechanism of Action Emission-computed tomography enhancers; Radiography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer metastases; Coronary artery disease
Most Recent Events
- 14 May 2007 Discontinued - Phase-I for Cancer metastases diagnosis in USA (IV)
- 05 Feb 2004 Photogen Technologies is now called IMCOR Pharmaceutical
- 02 Apr 2001 Phase-I clinical trials for Cancer metastases diagnosis in USA (IV)